Pembrolizumab Combo Extends Chemotherapy Benefit in Pancreatic Cancer

Release Date: 11-Aug-2020

For the clinical trial CheckMate-577 clinical trial, adjuvant nivolumab (Opdivo), was observed to deliver a prolonged disease -free survival in the patients who have been suffering from resected esophageal or gastroesophageal junction cancer when comapffed with placebo. The disease -free progression was observed to be improved in the patients because nivolumab was administered after chemoradiation therapy was deemed statistically. Other than this the trial has also shown some posistive results for the patients who were suffering from melanoma.

Before the conductance of this respective clinical trial, the patients suffering from esophageal cancer were only getting treated with chemoradiation therapy but the results obtained through the therapy were not delievering promising results.  The survival rate of the patients for the chemoradiation therapy was only 30%. The clinical trial for the mentioned study included 760 patients. Overall survival of the patients was the secondary point of the study.  Only the patients with stage II/III carcinoma of the esophagus or GEJ were allowed to get enrolled in the study. It was also compulsory that the patients enrolled in the study should have undergone pre-operative chemoradiotherapy followed by surgery.


Through the study, it was found that the drug was able to improve the overall disease -free survival in the patients. The drug also showed positive response towards managing the safety profile of the patients for a long period of time. According to the researchers who have been working on the trial, Opdvio for the treatment of resected esophageal or gastroesophageal junction cancer is the next standard of care for the patients. It is highly eligible in meeting the unmet needs of the patients and providing one stop for the patients who are in desperate need of an effective treatment.

Need custom market research solution? We can help you with that too.